Immunosuppression in corneal transplantation;L'immunosuppression dans la greffe de cornée

Journal Francais d'Ophtalmologie

Volumn 26, Issue 6, 2003, Pages 637-647

  Scheer, S ^a   Touzeau, O ^a   Borderie, V ^a   Laroche, L ^a  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

Author keywords

Corneal transplantation; Corticosteroids; Cyclosporin; Immunosuppression; Mycophenolate mofetil; Rejection; Tacrolimus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

BONE MARROW TOXICITY; CATARACT; CLINICAL TRIAL; CORNEA EPITHELIUM; CORNEA TRANSPLANTATION; DRUG ABSORPTION; DRUG DEVELOPMENT; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; GLAUCOMA; GRAFT FAILURE; GRAFT INFECTION; HIGH RISK POPULATION; HISTOCOMPATIBILITY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MALIGNANT TRANSFORMATION; NAUSEA; NONHUMAN; PARESTHESIA; REVIEW; SIDE EFFECT; SKIN DEFECT; STANDARD; T LYMPHOCYTE ACTIVATION;

ADRENAL CORTEX HORMONES; CORNEAL TRANSPLANTATION; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0142075750     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Borderie VM, Scheer S, Touzeau O, Vedié F, Carvajal-Gonzalez S, Laroche L. Donor coneal tissue selection before penetrating keratoplasty. Br J Ophthalmol, 1998;82:382-8.
2. Borderie V, Delbosc B, Kantelip B, Laroche L. Le rejet d'allogreffe de cornée. J Fr Ophtalmol, 1998;21:596-618.
3. Revillard JP. Immunologie. DeBoeck Université. Bruxelles. 1994.
4. Kaplan H, Streilein J. Immune response to immunization via the anterior chamber of the eye. I. F & lymphocyte-induced immune deviation. J Immunol, 1977;118:809-14.
5. Streilein J. Ocular immune privilege and the Faustian dilemna. Inv Ophthalmol Vis Sci, 1996;37:1940-50.
6. Griffith T, Brunner T, Fletcher S, Green D, Ferguson T. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 1995;270:1189-92.
7. Streilein J. Immune regulation and the eye: a dangerous compromise. FASEB, 1987;1:199-208.
8. Rocha G, Deschenes J, Rowsey J. The immunology of corneal graft rejection. Crit Rev Immunol, 1998;18:305-25.
9. Watanabe H, Gipson I. Detection of blood group differences in human corneal epithelium using a monoclonal antibody and lectins. Arch Ophthalmol, 1994;112:667-73.
10. Borderie VM, Lopez M, Vedié F, Laroche L. ABO antigen blood group compatibility in corneal transplantation. Cornea, 1997;16:1-6.
11. Collaborative Corneal Transplantation Studies Research Group. Effectiveness of histocompatibility matching in high risk corneal transplantation. Arch Ophthalmol, 1992;110:1392-403.
12. Maguire MG, Starck WJ, Gottisch JD, et al. Risk factors for corneal graft failure and rejections in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology, 1994;101:1356-547.
13. Hills JC, Make R, Watson P. Corticosteroids in corneal graft rejection: oral versus single pulse therapy. Ophthalmology, 1991;98:329-33.
14. Vabres B, Duffas M, Storck L, Pechereau A. Facteurs non immunologiques d'échec de greffe de cornée. Étude prospective sur 119 greffon au CHU de Nantes en 1995. J Fr Ophtalmol, 1999;22:33-8.
15. Belin MW, Bouchard CS, Phillips TM. Update on topical cyclosporin A. Background, immunology, and pharmacology. Cornea, 1990;9:184-95.
16. Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea, 1993;12:413-9.
17. Penn I. Why do immunosuppressed patients develop cancer? Crit Rev Oncogenesis, 1989;1:27-52.
18. BenEzra D, Maftzir G. Ocular penetration of cyclosporin A - The rabbit eye. Invest Ophthalmol Vis Sci, 1990;31:1362-6.
19. Vallelado AI, Lopez MI, Calonge M, Sanchez A, Alonso MJ. Efficacy and safety of microspheres of cyclosporin A, a new systemic formulation, to prevent corneal graft rejection. Curr Eye Res, 2002;24:39-45.
20. Reinhard T, Möller M, Sundmacher R. Penetrating keratoplasty in patients with atopic dermatitis with and without systemic cyclosporin A. Cornea, 1999;18:645-51.
21. Hill JC. Systemic Cyclosporin in high-risk keratoplasty- Short versus long term therapy. Ophthalmology, 1994;101:128-33.
22. Robert PY, Delbosc B, Preux PM, et al. Traitement par ciclosporine A à doses faibles, dans les kératoplasties transfixiantes à haut risque. Étude bicentrique de 90 cas. J Fr Ophtalmol, 1997;20:507-14.
23. Poon AC, Forbes JE, Dart JK, et al. Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study. Br J Ophthalmol, 2001;85:1464-9.
24. Algros MP, Angonin R, Delbosc B, Cahn JY, Kantelip B. Danger of systemic cyclosporine for corneal graft. Cornea, 2002;21:613-4.
25. Coster DJ, Shepherd WFI, Chin Fook T, Rice NCS, Jones BR. Prolonged survival of corneal allografts in rabbits treated with cyclosporin A. Lancet, 1979;29:688-9.
26. Niederkorn JY, Lang LS, Ross J, Mellon J, Robertson SM. Promotion of corneal allograft survival with Leflunomide. IOVS, 1994;35:3783-5.
27. Olsen TW, Gothard TW, Holland EJ. Misoprostol with cyclosporin A prolongs corneal allograft survival in an animal model. Cornea, 1996;15:76-81.
28. Rehany U, Waisman M. Suppression of corneal allograft rejection by systemic cyclosporine A in haevily vascularized rabbit corneas following alkali burns. Cornea, 1994;13:447-53.
29. Hoffmann F, Kruse HA, Meinhold H, et al. Interleukin-2 receptor - Targeted therapy by monoclonal antibodies in the rat corneal graft. Cornea, 1994;13:440-6.
30. Klebe S, Coupland SE, Krause L, Hoffmann F. Flow-cytometric analysis of peripheral lymphocytes in the rat following keratoplasty and immunosuppressive treatment. German J Ophthalmol; 1996;5:137-45.
31. Coupland SE, Krause L, Hoffmann F. The influence of penetrating keratoplasty and cyclosporin A therapy on MHC class II (Ia)-positive cells in the rat iris and choroid. Graefe's Arch Clin Exp Ophthalmol, 1996;234:116-24.
32. Sundmacher R, Reinhard T, Heering P. Six years' experience with systemic cyclosporin A prophylaxis in high-risk perforating keratoplasty patients. German J Ophthalmol, 1992;1:432-6.
33. Reinhard T, Sundmacher R, Godehardt E, Heering P. Systemische cyclosporin A-Prophylaxe nach keratoplastiken mit erhöhtem Risiko für Immunreaktionen als einzigem erhöhten risikofactor. Ophthalmologie, 1997;94:496-500.
34. Reinhard T, Sundmacher R, Heering P. Systemic ciclosporin A in high risk keratoplasties. Graefe's Arch Clin Exp Ophthalmol 1996;234:115-21.
35. Sundmacher R, Reinhard T. Central corneo-limbal transplantation under systemic ciclosporin A cover for severe limbal stem cell insufficiency. Graefe's Arch Clin Exp Ophthalmol, 1996;234:122-5.
36. Reinhard T, Sundmacher R. Perforierende Keratoplastik bei endogenem Ekzem. Eine Indikation für systemisches Ciclosporin A - Eine retrospektive Studie über 18 Patienten. Klin Mbl Augenheilk, 1992;201:159-63.
37. Mahlberg K, Uusitalo RJ, Oksala O. Prevention of high risk corneal graft rejection using cyclosporine A (CsA) incorporated into a collagen matrix. Ocular Immunol and Inflamm, 1997;5:101-10.
38. Gebhardt BM, Varnell ED, Kaufman HE. Cyclosporine in collagen particles: corneal penetration and suppression of allograft rejection. J Ocular Pharmacol Therap, 1995;11:509-17.
39. Juberias JR, Calonge M, Gomez S, et al. Efficacy of topical cyclosporine-loaded nanocapsules on keratoplasty rejection in the rat. Curr Eye Res, 1998;17:39-46.
40. Milani JK, Pleyer U, Dukes A, et al. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmol, 1993;100:890-6.
41. Minguez E, Tiestos MT, Cristobal JA, et al. Absorption intra-oculaire du collyre ciclosporine A. J Fr Ophtalmol, 1992;15:263-7.
42. Diaz-Llopis M, Menezo JL. Penetration of 2% cyclosporin eyedrops into human aqueous humor. Br J Ophthalmol, 1989;73:600-3.
43. Perry HD, Donnenfeld ED, Acheampong A, et al. Topical cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0,5% cyclosporine A into the cornea and anterior chamber. CLAO J, 1998;24:159-65.
44. Zhao JC, Jin XY. Local therapy of corneal allograft rejection with cyclosporine. Am J Ophthalmol, 1994;119:189-94.
45. Inoue K, Amano S, Fujita N, et al. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Jpn J Ophthalmol 2000;44:302-5.
46. Belin MW, Bouchard CS, Frantz S, Chmielinska J. Topical cyclosporin in high risk corneal transplants. Ophthalmology, 1989;96:1141-50.
47. Benelli U, Ross JR, Nardi M, Klintworth GK. Corneal neovascularization induced by xenograft or chemical cautery. Inhibition by Cyclosporin A. Invest Ophthalmol Vis Sci, 1997;38:274-82.
48. Touzeau O, Borderie VM, Laroche L. Corneal limbus carcinoma in a patient treated by systemic cyclosporin after heart transplantation. N Eng J Med, 1999;341:374-5.
49. Maske R, Hill JC, Horak S. Mixed lymphocytes culture responses in rabbits undergoing corneal grafting and topical cyclosporine treatment. Cornea 1994;13:324-30.
50. Holland E, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea, 1993;12:413-9.
51. Gündüz K, Ozdemir O. Therapeutic use of topical cyclosporine. Ann Ophthalmol, 1993;25:182-6.
52. Perry HD, Doshi SJ, Donnenfeld ED, Bai GS. Topical cycloporin A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea, 2002;21:161-3.
53. Touzeau O, Borderie V, Razavi S, Warnet JM, Laroche L. Utilisation topique de ciclosporine dans une kératopathie microcristalline à Streptocoque. J Fr Ophtalmol 1999;22:662-5.
54. Perry HD, Donnenfeld ED, Kanellopoulos AJ, Grossman GA. Topical cyclosporin A in the management of postkeratoplasty glaucoma. Cornea, 1997;16:284-8.
55. Nishi M, Herbort CP, Matsubara M, et al. Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. Invest Ophthalmol Vis Sci, 1993;34:2477-86.
56. Hikita N, Lopez JS, Chan CC, Mochizuki M, Nussenblatt RB, de Smet MD. Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci, 1997;38:901-9.
57. Okada K, Sakata H, Minamoto A, Fujihara M. Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. Ophthalmologica, 1996;210:175-9.
58. Dickey JB, Cassidy EM, Bouchard CS. Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. Cornea, 1993;12:204-7.
59. Minamoto A, Sakata H, Okada K, Fujihara M. Suppression of corneal graft rejection by subconjunctival injection of FK-506 in a rat model of penetrating keratoplasty. Jpn J Ophthalmol, 1995;39:12-9.
60. Mills RA, Jones DB, Winkler CR, Wallace GW, Wilhelmus KR. Topical FK-506 prevents experimental corneal allograft rejection. Cornea, 1995;14:157-60.
61. Reinhard T, Reis A, Mayweg S, Oberhuber H, Mathis G, Sundmacher R. Topical Fk506 in inflammatory corneal and conjunctival diseases. Klin Monatsbl Augenheilkd, 2002;219:125-31.
62. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology, 2001;108:1838-44.
63. Reis A, Reinhard T, Sundmacher R, Braunstein C, Godehardt E. Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Br J Ophthalmol, 1998;82:700-3.
64. Reis A, Reinhard T, Sundmacher R, Braunstein S, Godehardt E. Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. Transplant Proc, 1998;30:4344-7.
65. Reinhard T, Reis A, Kutkuhn B, Voiculescu A, Sundmacher R. Mycophenolate mofetil after penetrating high risk keratoplasty. A pilot study. Klin Monatsbl Augenheilkd, 1999;215:201-2.
66. Reis A, Reinhard T, Voiculescu A, Mayer K, Sundmacher R. Highly active antiviral and immunosuppressive combination therapy with acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease. Klin Monatsbl Augenheilkd, 2001;218:183-6.
67. Reis A, Reinhard T, Voilescu A, et al. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol, 1999;83:1268-71.
68. Reinhard T, Reis A, Bohringer D, et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol, 2001;239:367-72.